# the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C

> **NCT06132360** · PHASE1 · COMPLETED · sponsor: **Shanghai Rona Therapeutics Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- To Reduce the LDL-C Level in Hypercholesteremia Patients

## Interventions

- **DRUG:** RN0191

## Key facts

- **NCT ID:** NCT06132360
- **Lead sponsor:** Shanghai Rona Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-18
- **Primary completion:** 2024-07-02
- **Final completion:** 2024-09-23
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132360, "the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06132360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*